Compare CLDT & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDT | EOLS |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.9M | 304.0M |
| IPO Year | 2010 | 2018 |
| Metric | CLDT | EOLS |
|---|---|---|
| Price | $7.48 | $4.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $9.50 | ★ $17.40 |
| AVG Volume (30 Days) | 243.2K | ★ 1.1M |
| Earning Date | 02-25-2026 | 03-03-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $301,376,000.00 | $285,823,000.00 |
| Revenue This Year | N/A | $13.70 |
| Revenue Next Year | N/A | $13.40 |
| P/E Ratio | $618.58 | ★ N/A |
| Revenue Growth | N/A | ★ 15.10 |
| 52 Week Low | $5.83 | $4.09 |
| 52 Week High | $8.58 | $17.12 |
| Indicator | CLDT | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.76 | 32.77 |
| Support Level | $7.39 | $4.09 |
| Resistance Level | $7.80 | $4.61 |
| Average True Range (ATR) | 0.21 | 0.26 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 63.44 | 24.34 |
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.